个人中心 - 老虎社区

SebZz

IP属地：未知

帖子 · 47帖子 · 47
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- SebZzSebZz
  ·2021-12-24
  Ok
  非常抱歉，此主贴已删除
  1,821 2
  9
  分享
  举报
- SebZzSebZz
  ·2021-12-24
  Ok
  非常抱歉，此主贴已删除
  2,575 1
  3
  分享
  举报
- SebZzSebZz
  ·2021-12-06
  Nice
  Apple Stock Is an Attractive Buy, Says KeyBanc. Price Target Set at $191.
  Apple shares were rising Monday after analysts at KeyBanc Capital Markets initiated coverage on the
  Apple Stock Is an Attractive Buy, Says KeyBanc. Price Target Set at $191.
  2,210 评论
  2
  分享
  举报
- SebZzSebZz
  ·2021-12-03
  Nice
  Clover Stock Has Slumped. Buy the Dip?
  Clover Health stock has been struggling in the past few months. Shares have reached 80% lower since
  Clover Stock Has Slumped. Buy the Dip?
  2,240 评论
  1
  分享
  举报
- SebZzSebZz
  ·2021-12-02
  Nice
  Novartis Says Top Drugs Should Fuel Sales Growth Through 2026
  Novartis AG said Thursday ahead of its research-and-development day starting later today that it exp
  Novartis Says Top Drugs Should Fuel Sales Growth Through 2026
  1,862 评论
  3
  分享
  举报
- SebZzSebZz
  ·2021-11-30
  Evil
  非常抱歉，此主贴已删除
  2,275 评论
  1
  分享
  举报
- SebZzSebZz
  ·2021-11-30
  Nic3
  非常抱歉，此主贴已删除
  2,204 评论
  3
  分享
  举报
- SebZzSebZz
  ·2021-11-29
  Nice
  非常抱歉，此主贴已删除
  2,448 评论
  点赞
  分享
  举报
- SebZzSebZz
  ·2021-11-29
  Nice
  非常抱歉，此主贴已删除
  3,200 评论
  点赞
  分享
  举报
- SebZzSebZz
  ·2021-11-28
  Ok
  非常抱歉，此主贴已删除
  2,100 评论
  3
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3571302905057300","uuid":"3571302905057300","gmtCreate":1608209527730,"gmtModify":1608209527730,"name":"SebZz","pinyin":"sebzz","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":8,"tweetSize":47,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":698827967,"gmtCreate":1640346251244,"gmtModify":1640346251351,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698827967","repostId":"2193127176","repostType":4,"isVote":1,"tweetType":1,"viewCount":1821,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698827045,"gmtCreate":1640346239313,"gmtModify":1640346239379,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698827045","repostId":"1142015669","repostType":4,"isVote":1,"tweetType":1,"viewCount":2575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606052903,"gmtCreate":1638802796173,"gmtModify":1638802796260,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606052903","repostId":"1107494736","repostType":4,"repost":{"id":"1107494736","kind":"news","pubTimestamp":1638799191,"share":"https://www.laohu8.com/m/news/1107494736?lang=&edition=full","pubTime":"2021-12-06 21:59","market":"us","language":"en","title":"Apple Stock Is an Attractive Buy, Says KeyBanc. Price Target Set at $191.","url":"https://stock-news.laohu8.com/highlight/detail?id=1107494736","media":"Barrons","summary":"Apple shares were rising Monday after analysts at KeyBanc Capital Markets initiated coverage on the ","content":"<p>Apple&nbsp;shares were rising Monday after analysts at KeyBanc Capital Markets initiated coverage on the stock with a bullish outlook, citing growth in the tech giant’s services segment.</p>\n<p>Analyst Brandon Nispel rated the stock Overweight with a $191 price target. The target presents an 18% increase from Apple’s (ticker: AAPL) $161.84 closing price on Friday. The stock was up 1.2% to $163.73 in premarket trading Monday.</p>\n<p>Of the 42 analysts covering the stock surveyed by FactSet, 32 have it at a Buy or Overweight rating, nine rated it at Hold, and one rated it Underweight.</p>\n<p>“While AAPL is expensive by historical valuations, we find AAPL attractive relative to other mega-caps,” Nispel wrote on Monday.</p>\n<p>The analyst outlined three main reasons for his bullish take. Nispel doesn’t believe iPhone unit sales have peaked, with the 5G upgrade cycle potentially pushing Apple past its current peak; he believes the company has managed to increase its product breadth to reduce reliability on iPhone sales; and he foresees services to grow at rates multiple times faster than user growth.</p>\n<p>The analyst forecasts Apple to have 1.09 billion active iPhones and 1.8 billion active installed devices by the end of the first quarter of the 2022 fiscal year. This presents a 7% and 8% year-over-year increase, respectively.</p>\n<p>“This shows a healthy growing user base where Apple iPhone market share is low relative to key geographies outside the United States,” Nispel wrote. “As the installed base grows, a larger base can support more sales on lower upgrade rates.”</p>\n<p>Apple’s international segment is likely to grow faster in the coming years as other countries adapt to 5G, prompting a wave of upgrades to compatible hardware, Nispel wrote. He estimates every 1% increase in 5G upgrade rates could drive an incremental 11 million iPhone unit sales.</p>\n<p>As hardware adoption grows, so does Apple’s services business. The segment, which includes services such as Apple TV+, Music, News+, AppleCare, Advertising, and Cloud, has grown 27% in the 2021 fiscal year. Over time, it could become a key profitability driver, growing to more than $100 billion by 2024, Nispel said.</p>\n<p>Nispel recognized that Apple’s App Store legal battles were concerning, but were “likely more a bend, not break outcome.” The company has had to make modest changes to its App Store guidance in response to court rulings and regulatory changes, including lowering its commission for some developers. It will likely make more concessions over time, such as allowing developers to provide third-party payment options, Nispel said.</p>\n<p>“We expect regulation to take time to implement, and believe Apple’s competitive advantage is unlikely to be substantially harmed,” he added.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock Is an Attractive Buy, Says KeyBanc. Price Target Set at $191.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock Is an Attractive Buy, Says KeyBanc. Price Target Set at $191.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 21:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/apple-aapl-stock-attractive-buy-51638798446?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple shares were rising Monday after analysts at KeyBanc Capital Markets initiated coverage on the stock with a bullish outlook, citing growth in the tech giant’s services segment.\nAnalyst Brandon ...</p>\n\n<a href=\"https://www.barrons.com/articles/apple-aapl-stock-attractive-buy-51638798446?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.barrons.com/articles/apple-aapl-stock-attractive-buy-51638798446?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107494736","content_text":"Apple shares were rising Monday after analysts at KeyBanc Capital Markets initiated coverage on the stock with a bullish outlook, citing growth in the tech giant’s services segment.\nAnalyst Brandon Nispel rated the stock Overweight with a $191 price target. The target presents an 18% increase from Apple’s (ticker: AAPL) $161.84 closing price on Friday. The stock was up 1.2% to $163.73 in premarket trading Monday.\nOf the 42 analysts covering the stock surveyed by FactSet, 32 have it at a Buy or Overweight rating, nine rated it at Hold, and one rated it Underweight.\n“While AAPL is expensive by historical valuations, we find AAPL attractive relative to other mega-caps,” Nispel wrote on Monday.\nThe analyst outlined three main reasons for his bullish take. Nispel doesn’t believe iPhone unit sales have peaked, with the 5G upgrade cycle potentially pushing Apple past its current peak; he believes the company has managed to increase its product breadth to reduce reliability on iPhone sales; and he foresees services to grow at rates multiple times faster than user growth.\nThe analyst forecasts Apple to have 1.09 billion active iPhones and 1.8 billion active installed devices by the end of the first quarter of the 2022 fiscal year. This presents a 7% and 8% year-over-year increase, respectively.\n“This shows a healthy growing user base where Apple iPhone market share is low relative to key geographies outside the United States,” Nispel wrote. “As the installed base grows, a larger base can support more sales on lower upgrade rates.”\nApple’s international segment is likely to grow faster in the coming years as other countries adapt to 5G, prompting a wave of upgrades to compatible hardware, Nispel wrote. He estimates every 1% increase in 5G upgrade rates could drive an incremental 11 million iPhone unit sales.\nAs hardware adoption grows, so does Apple’s services business. The segment, which includes services such as Apple TV+, Music, News+, AppleCare, Advertising, and Cloud, has grown 27% in the 2021 fiscal year. Over time, it could become a key profitability driver, growing to more than $100 billion by 2024, Nispel said.\nNispel recognized that Apple’s App Store legal battles were concerning, but were “likely more a bend, not break outcome.” The company has had to make modest changes to its App Store guidance in response to court rulings and regulatory changes, including lowering its commission for some developers. It will likely make more concessions over time, such as allowing developers to provide third-party payment options, Nispel said.\n“We expect regulation to take time to implement, and believe Apple’s competitive advantage is unlikely to be substantially harmed,” he added.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":2210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601607958,"gmtCreate":1638517719122,"gmtModify":1638517719122,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601607958","repostId":"1138290638","repostType":4,"repost":{"id":"1138290638","kind":"news","pubTimestamp":1638515006,"share":"https://www.laohu8.com/m/news/1138290638?lang=&edition=full","pubTime":"2021-12-03 15:03","market":"us","language":"en","title":"Clover Stock Has Slumped. Buy the Dip?","url":"https://stock-news.laohu8.com/highlight/detail?id=1138290638","media":"TheStreet","summary":"Clover Health stock has been struggling in the past few months. Shares have reached 80% lower since ","content":"<p>Clover Health stock&nbsp;has been struggling in the past few months. Shares have reached 80% lower since the early June peak as CLOV’s “meme” momentum faded.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/528f59c934a300195181e1a4f4dda4a0\" tg-width=\"1240\" tg-height=\"698\" width=\"100%\" height=\"auto\"><span>Figure 1: Clover Health logo.</span></p>\n<p>Now, CLOV has hit bottom as shares trade at all-time lows of less than $5. Below, we have listed a few questions that could help determine if now is the time to invest in the stock.</p>\n<p><b>The success of Clover Assistant</b></p>\n<p>AI software platform Clover Assistant is the key differentiator in Clover’s unique model, and it has nearly 100,000 lives under management. The platform was designed to help physicians improve their services and attract new members.</p>\n<p>Clover’s business model is heavily dependent on the platform, but experts are skeptical as to whether it can deliver what it promises: ease of use for doctors and money saving opportunities for patients. Clover Assistant has grown 223% YOY and&nbsp;approximately&nbsp;2,900 health care professionals used Clover Assistant in Q3, up 45% YOY.</p>\n<p><b>Are bears right?</b></p>\n<p>Known as the “king of SPACs,” Clover saw its stock price plummet earlier this year. The likely culprit: research firm Hindenburgshortedthe stock, claiming that the company was the target of an investigation for dubious sales practices.</p>\n<p>After Hindenburg's bet, CLOV share price plunged 50% year-to-date by the end of May. At that point, the stock caught the attention of Wall Street Bets’ “apes” community and became a target of meme mania. Since early June, stocks spiked 190% but then fell around 80% to all-time lows.</p>\n<p>Venture capitalist Chamath Palihapitiya, who helped Clover go public through SPAC,defended&nbsp;the company from the allegations. But at that point, it may have been too late: skepticism towards CLOV had spread wide and the stock became a short seller favorite.</p>\n<p>Currently, short interest is a bit on the hot side: 12% of the float is currently shorted,according&nbsp;to Yahoo Finance. We like to think that anything above 10% is a bearish indicator and a potential short squeeze candidate.</p>\n<p><b>CLOV’s path to profitability</b></p>\n<p>Clover Health’s “meme” momentum driven by sheer buzz and enthusiasm seems to have lost steam as the main discussion boards “cooled down” on the name. Now, CLOV shares could trade more in line with business fundamentals.</p>\n<p>In that regard, the company has been a strong revenue generator in a&nbsp;market&nbsp;with multi-billion dollar potential: Medicare Advantage. In Q3, Clover&nbsp;generated&nbsp;$472 million in revenues, up an astounding 153% YOY. However, the company is still far from being profitable. Full year 2021 adjusted EBITDA is&nbsp;expected&nbsp;to sit around negative $250 million and $230 million.</p>\n<p>One key question is how long it may take for Clover to reach profits with the current business model. Another is whether the company will be able to expand outside its current territory. The answers to these questions will likely drive the stock’s performance in the foreseeable future.</p>\n<p>Lastly, according to Wall Street experts, CLOV stock is&nbsp;undervalued&nbsp;at current levels. Despite the consensus rating on the stock leaning heavily towards cautious, average price target sits at $8.67, suggesting 76% upside potential from here.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Stock Has Slumped. Buy the Dip?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Stock Has Slumped. Buy the Dip?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 15:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/clov/clov-stock-has-hit-rock-bottom-time-to-buy><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Clover Health stock has been struggling in the past few months. Shares have reached 80% lower since the early June peak as CLOV’s “meme” momentum faded.\nFigure 1: Clover Health logo.\nNow, CLOV has hit...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/clov/clov-stock-has-hit-rock-bottom-time-to-buy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://www.thestreet.com/memestocks/clov/clov-stock-has-hit-rock-bottom-time-to-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138290638","content_text":"Clover Health stock has been struggling in the past few months. Shares have reached 80% lower since the early June peak as CLOV’s “meme” momentum faded.\nFigure 1: Clover Health logo.\nNow, CLOV has hit bottom as shares trade at all-time lows of less than $5. Below, we have listed a few questions that could help determine if now is the time to invest in the stock.\nThe success of Clover Assistant\nAI software platform Clover Assistant is the key differentiator in Clover’s unique model, and it has nearly 100,000 lives under management. The platform was designed to help physicians improve their services and attract new members.\nClover’s business model is heavily dependent on the platform, but experts are skeptical as to whether it can deliver what it promises: ease of use for doctors and money saving opportunities for patients. Clover Assistant has grown 223% YOY and approximately 2,900 health care professionals used Clover Assistant in Q3, up 45% YOY.\nAre bears right?\nKnown as the “king of SPACs,” Clover saw its stock price plummet earlier this year. The likely culprit: research firm Hindenburgshortedthe stock, claiming that the company was the target of an investigation for dubious sales practices.\nAfter Hindenburg's bet, CLOV share price plunged 50% year-to-date by the end of May. At that point, the stock caught the attention of Wall Street Bets’ “apes” community and became a target of meme mania. Since early June, stocks spiked 190% but then fell around 80% to all-time lows.\nVenture capitalist Chamath Palihapitiya, who helped Clover go public through SPAC,defended the company from the allegations. But at that point, it may have been too late: skepticism towards CLOV had spread wide and the stock became a short seller favorite.\nCurrently, short interest is a bit on the hot side: 12% of the float is currently shorted,according to Yahoo Finance. We like to think that anything above 10% is a bearish indicator and a potential short squeeze candidate.\nCLOV’s path to profitability\nClover Health’s “meme” momentum driven by sheer buzz and enthusiasm seems to have lost steam as the main discussion boards “cooled down” on the name. Now, CLOV shares could trade more in line with business fundamentals.\nIn that regard, the company has been a strong revenue generator in a market with multi-billion dollar potential: Medicare Advantage. In Q3, Clover generated $472 million in revenues, up an astounding 153% YOY. However, the company is still far from being profitable. Full year 2021 adjusted EBITDA is expected to sit around negative $250 million and $230 million.\nOne key question is how long it may take for Clover to reach profits with the current business model. Another is whether the company will be able to expand outside its current territory. The answers to these questions will likely drive the stock’s performance in the foreseeable future.\nLastly, according to Wall Street experts, CLOV stock is undervalued at current levels. Despite the consensus rating on the stock leaning heavily towards cautious, average price target sits at $8.67, suggesting 76% upside potential from here.","news_type":1,"symbols_score_info":{"CLOV":0.9}},"isVote":1,"tweetType":1,"viewCount":2240,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603567349,"gmtCreate":1638429661733,"gmtModify":1638429661852,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603567349","repostId":"1159695915","repostType":4,"repost":{"id":"1159695915","kind":"news","pubTimestamp":1638429346,"share":"https://www.laohu8.com/m/news/1159695915?lang=&edition=full","pubTime":"2021-12-02 15:15","market":"us","language":"en","title":"Novartis Says Top Drugs Should Fuel Sales Growth Through 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1159695915","media":"Marketwatch","summary":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it exp","content":"<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.</p>\n<p>The Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.</p>\n<p>\"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.</p>\n<p>Novartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Says Top Drugs Should Fuel Sales Growth Through 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Says Top Drugs Should Fuel Sales Growth Through 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-02 15:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click><strong>Marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while...</p>\n\n<a href=\"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"source_url":"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1159695915","content_text":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.\nThe Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.\n\"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.\nNovartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.","news_type":1,"symbols_score_info":{"NVS":0.9}},"isVote":1,"tweetType":1,"viewCount":1862,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609958605,"gmtCreate":1638233759561,"gmtModify":1638233759645,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Evil","listText":"Evil","text":"Evil","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609958605","repostId":"2187309641","repostType":4,"isVote":1,"tweetType":1,"viewCount":2275,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609951321,"gmtCreate":1638233680704,"gmtModify":1638233688949,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Nic3","listText":"Nic3","text":"Nic3","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609951321","repostId":"1122315710","repostType":2,"isVote":1,"tweetType":1,"viewCount":2204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600248704,"gmtCreate":1638164444630,"gmtModify":1638164444630,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600248704","repostId":"1129316714","repostType":4,"isVote":1,"tweetType":1,"viewCount":2448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600248241,"gmtCreate":1638164393395,"gmtModify":1638164393395,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600248241","repostId":"2187327727","repostType":4,"isVote":1,"tweetType":1,"viewCount":3200,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600335037,"gmtCreate":1638065477252,"gmtModify":1638065477252,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600335037","repostId":"2186287173","repostType":4,"isVote":1,"tweetType":1,"viewCount":2100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}